Is it Good Time to Bail on AcelRx Pharmaceuticals Inc. [ACRX]? Let’s Look at the Charts

AcelRx Pharmaceuticals Inc. [ACRX] has traded in a range of $0.70 to $2.50 in the last 1 year. As of this writing, the stock is at $1.51, up 5.94%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, ACRX shares are -7.14% down with the monthly amount drift of -21.43% and seems bad in a long time frame.

On 4, December 2020, AcelRx Pharmaceuticals Announces Partnership with the National Rural Health Association. According to news published on Yahoo Finance, AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a partnership with the National Rural Health Association (NRHA) focused on the co-development and execution of a strategic marketing plan to educate and promote DSUVIA® (sufentanil sublingual tablet 30 mcg) in line with the NRHA mission to its members.

Analyst Birdseye View:

The most recent analyst activity for AcelRx Pharmaceuticals Inc. [NASDAQ:ACRX] stock was on November 11, 2019, when it was Downgrade with a Neutral rating from Credit Suisse, which also lowered its 12-month price target on the stock from $7 to $2. On August 05, 2019, Credit Suisse Resumed an Outperform rating. On July 10, 2019, Credit Suisse Resumed an Outperform rating. On April 24, 2019, B. Riley FBR Resumed a Buy rating and increased its price target to $6.50. On February 15, 2019, Credit Suisse Initiated an Outperform rating and boosted its amount on this stock to $7. On October 23, 2018, B. Riley FBR Initiated a Buy rating and boosted its target amount on this stock to $9. RBC Capital Mkts elevated its amount target by recapitulating a higher weight for this stock.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.70 and a peak of $2.50. Right now, the middling Wall Street analyst 12-month amount mark is $5.00. At the most recent market close, shares of AcelRx Pharmaceuticals Inc. [NASDAQ:ACRX] were valued at $1.51.

FUNDAMENTAL ANALYSIS

AcelRx Pharmaceuticals Inc. [NASDAQ:ACRX] most recently reported quarterly sales of 1.37 billion, which represented growth of 133.30%. This publicly-traded organization’s revenue is $23,121 per employee, while its income is -$537,778 per employee. This company’s Gross Margin is currently -23.20%, its Pretax Margin is -2325.78, and its Net Margin is -2325.91.

The Principal structure of this organization shows its whole liability to whole principal at 151.53 and the whole liability to whole assets at 133.32. It shows enduring liability to the whole principal at 144.13 and enduring liability to assets at 1.27 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.4100 points at 1st support level, the second support level is making up to 1.3900. But as of 1st resistance point, this stock is sitting at 1.4600 and at 1.4900 for 2nd resistance point.

AcelRx Pharmaceuticals Inc. [ACRX] reported its earnings at -$0.1 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.08/share signifying the difference of -0.02 and -25.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.08 calling estimates for -$0.14/share with the difference of 0.06 depicting the surprise of 42.90%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for AcelRx Pharmaceuticals Inc. [NASDAQ:ACRX] is 2.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 4.86. Now if looking for a valuation of this stock’s amount to sales ratio it’s 72.99.

Insider Stories

The most recent insider trade was by Angotti Vincent J., Chief Executive Officer, and it was the purchase of 7547.0 shares on Jun 15.